New drug cocktail targets Hard-to-Treat cancers in early trial
NCT ID NCT03065387
First seen Jan 12, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This early-phase study tests a combination of the drug neratinib with either everolimus, palbociclib, or trametinib in people with advanced solid tumors that have not responded to standard treatments. The tumors must have specific gene changes (EGFR, HER2, HER3, HER4, or KRAS). The main goal is to find the safest dose and understand side effects. About 93 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.